Brain cholesterol metabolism, oxysterols, and dementia

Journal of Alzheimer's Disease

Volumn 33, Issue 4, 2013, Pages 891-911

  Hughes, Timothy M ^a   Rosano, Caterina ^a   Evans, Rhobert W ^a   Kuller, Lewis H ^a  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

24 hydroxycholesterol; 24S hydroxycholesterol; Alzheimer's disease; brain; dementia; oxysterols

Indexed keywords

24S HYDROXYCHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL; OXYSTEROL; UNCLASSIFIED DRUG;

CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; HUNTINGTON CHOREA; LIPID BLOOD LEVEL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84873661818     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121585     Document Type: Review

References (55)

1. Foley P (2010) Lipids in Alzheimer's disease: A century-old story. Biochim Biophys Acta 1801, 750-753
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J,Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, NothenMM,Moebus S, Jockel K-H, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093
3. Di Paolo G, Kim T-W (2011) Linking lipids to Alzheimer's disease: Cholesterol and beyond. Nat Rev Neurosci 12, 284-296
4. Kivipelto M, Helkata E (2002) Apolipoprotein E4 allele, elevated midlife total cholesterol and high midlife systolic blood pressure are independent risk factors for late life Alzheimer's disease. Ann Intern Med 279, 985-989
5. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 2, CD003160
6. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P (2010) Statins for the treatment of dementia. Cochrane Database of Syst Rev 8, CD007514
7. Bjorkhem I (2006) Crossing the barrier: Oxysterols as cholesterol transporters and metabolic modulators in the brain. J Internal Med 260, 493-508
8. Papassotiropoulos A, Streffer J, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lutjohann D, Ghebremedhin E, Hegi T, Pasch T, Traxler M, Bruhl A, Benussi L, Binetti G, Braak H, Nitsch R, Hock C (2003) Increased brain beta-Amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60, 29-35
9. Garcia A, Muniz M, Souza e Silva H, da Silva H, Athayde-Junior L (2009) Cyp46 polymorphisms in Alzheimer's disease: A review. J Mol Neurosci 39, 342-345
10. LeoniV(2009) Oxysterols as markers of neurological disease -A review. Scan J Clin Lab Invest 69, 22-25
11. Umetani M, Shaul P (2011) 27-Hydroxycholesterol: The first identified endogenous SERM. Trends Endocrinol Metab 22, 130-135
12. Snipes G, Suter U (1997) Cholesterol and myelin. Subcell Biochem 28, 173-204
13. Bartzokis G (2011) Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 32, 1341-1371
14. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Bjorkhem I (2001) On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314, 45-48
15. Fassbender K, Stoick M, Bertsch T, Ragoschke A, Kuehl S, Walter S, Walter J, Brechtel K, Muehlhauser F, Von Bergmann K, Lutjohann D (2002) Effects of statins on cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59, 1699-1258
16. Barrett P, Song Y, Van Horn W, Hustedt E, Schafer J, Hadziselimovic A, Beel A, Sanders C (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171
17. Brown A, JessupW(2009) Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol hoeostasis. Mol Aspects Med 30, 111-122
18. Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination of cholesterols oxidation products in human plasma by isotope dilution-mass spectroscopy. Anal Biochem 225, 73-80
19. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund L, Diczfalusy U, Hillert J, Bjorkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191
20. Leoni V, Shafaati M, Solomon A (2006) Are the CSF levels of 24S-hydroxyxholesterol a sensitive biomarker or mild cognitive impairment? Neurosci Lett 397, 83-87
21. Teunissen C, De Vente J, Steinbusch H, De Bruijn C (2003) Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 24, 147-155
22. van den Kommer T, Dik M, Comijs H, Fassbender K, Lutjohann D, Jonker C (2009) Total cholesterol and oxysterols: Early markers for cognitive decline in elderly? Neurobiol Aging 30, 534-545
23. Burkard I, Rentsch K, von Eckardstein A (2004) Determination of 24S-And 27-hydroxycholesterol in plasma by high-performance liquid chromatography-mass spectrometry. J Lipid Res 45, 776-781
24. DeBarber A, Lujohann D, Merkens L, SteinerR(2008) Liquid chromatography-Tandem mass spectrometry determination of plasma 24 S-hydroxycholesterol with chromatographic separation of 25-hydroxycholesterol. Anal Biochem 381, 151-153
25. Matsunaga I, Hakamata H, Sadohara K, Kakiuchi K, Kusu F (2009) Determination of oxysterols in oxidatively modified low-density lipoprotein by semi-micro high-performance liquid chromatography with electrochemical detection. Anal Biochem 393, 22-28
26. Bretillon L, Siden A, Wahlund L, Lutjohann D, Minthon L, Crisby M, Hillert J, Groth C, Diczfalusy U, Bjorkhem I (2000) Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 293, 87-90
27. Papassotiropoulus A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao M, Maier W, Bjorkhem I, von Bergmann K, Heun R (2000) Plasma 24S- hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. NeuroReport 26, 1959-1962
28. Lutjohann D, Papasotiropoulus A, Bjorkhem I, Locatelli S, Bagli M, Oehring R, Schlegel U, Jessen F, Rao M, von Bergmann K, Heun R (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular dementia patients. J Lipid Res 41, 195-198
29. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schroder J (2002) Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 324, 83-85
30. Teunissen C, Lutjohann D, von Bergmann K,Verhey F, Vreeling F,Wauters A, Bosmans E, Bosma H, van Boxtel M, Maes M, Delanghe J, Blom H, Verbeek M, Rieckmann P, De Bruijn C, Steinbusch H, de Vente J (2003) Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 24, 893-902
31. Heverin M, Bagdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the level of cerebral and extracerebral sterols in the brain of patient with Alzheimer's disease. J Lipid Res 45, 186-192
32. Kolsch H, Heun R, Kerksiek A, Bergmann K, Maier W, Lutjohann D (2004) Altered levels of plasma 24S-And 27-hydroxycholesterol in demented patients. Neurosci Lett 368, 303-308
33. Shafaati M, Solomon A, Kivipelto M, Bjorkhem I, Leoni V (2007) Levels of ApoE in cerebral fluid are correlated with Tau and 24S-hydroxyxholesterol in patients with cognitive disorders. Neurosci Lett 425, 78-82
34. Leoni V, Masterman T (2002) Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 331, 163-166
35. Karrenbauer V, Leoni V, Lim E, Giovannoni G, Ingle G, Sastre-Garriga J, Thompson A, Rashid W, Davies G, Miller D, Bjorkhem I, Masterman T (2006) Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg 108, 456-460
36. Thelen K, Falkai R, Bayer T, Lutjohann D (2006) Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett 403, 15-19
37. Leoni V, Mariotti C (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131 (Pt 11) 2851-2859
38. Koschack J, Lutjohann D, Schmidt-Samoa C, Irle E (2009) Serum 24S-hydroxycholesterol and hippocampal size in middle-Aged normal individuals. Neurobiol Aging 30, 898-902
39. Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard A, Julin P, Svensson L, Wahlund L, Andreasen N, Winblad B, Soininen H, Bjorkhem I (2009) Plasma levels of 24Shydroxycholesterol reflect brain volumes in patients without objective cognitive impairments but not with Alzheimer's disease. Neurosci Lett 462, 89-93
40. Zuliani G, Donnorso M, Bosi C, Passaro A, Dalla Nora E, Zurlo A, Bonetti F, Mozzi A, Cortese C (2011) Plasma 24Shydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: A case-control study. BMC Neurology 11, 121
41. Besga A, Cedazo-Minguez A, Kareholt I, Solomon A, Bjorkhem I, Winblad B, Leoni V, Hooshmand B, Spulber G, Gonzalez-Pinto A, Kivipelto M, Wahlund L (2012) Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms. Neurosci Lett 510, 121-126
42. Babiker A, Diczfalusy U (1998) Transport of side-chain oxidized oxysterols in the human circulation. Biochim Biophys Acta 1392, 333-339
43. Hughes T, Kuller L, Lopez O, Becker J, Evans R, Sutton-Tyrrell K, Rosano C (2012) Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. J Alzheimers Dis 30, 53-61
44. Vega G, Weiner M, Kolsch H, von Bergmann K, Heun R, Lutjohan D, Nguyen A, Moore C (2004) The effects of gender and CYP46 and ApoE polymorphism on 24Shydroxycholesterol levels in Alzheimer's patients treated with statins. Curr Alzheimer Res 1, 71-77
45. Abildayeva K, Jansen P, Hirsch-Reinshagen V, Bloks V, Bakker A, Ramaekers F, de Vente J, Groen A, Wellington C, Kuipers F, MulderM(2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 281, 12799-12808
46. Leoni V, Masterman T (2003) Side chain oxidized oxysterols in cerebrospinal fluid and the integity of blood-brain and blood fluid barriers. J Lipid Res 44, 793-799
47. Papassotiropoulus A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevetated in early stages of dementia. J Psychiatr Res 36, 27-32
48. Fotenos A, Snyder A (2005) Normative estimates of crosssectional and longitudinal brain volume decline in aging and AD. Neurology 64, 1032-1039
49. Botti R, Triscari J (1991) Concentrations of provastatin and lovastatin in the cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14, 256-261
50. DeKosky S (2005) Statin therapy in the treatment of Alzheimer disease: What is the rationale? Am J Med 12A, 48-53
51. Locatelli S, Lutjohann D (2002) Reduction of plasma 24Shydroxycholesterol levels using high-dosage simvastatin in patients with hypercholesteroemia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59, 213-216
52. Thelen K, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D (2006) High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol 46, 812-816
53. Holdenrieder S, Lutjohann D (2004) Does brain specific 24S-hydroxycholesteroll in plasma indicate the disruption of blood-brain barrier in patients with ischemic stroke? Neurosci Lett 368, 201-204
54. Teunissen C, Dijkstra C, Polman C, Hoogervorst E, von Bergmann K, Lutjohann D (2003) Decreased levels of the brain specific 24S-hydroxychoesterol and cholesterol in serum of multiple sclerosis patients. Neurosci Lett 347, 159-162
55. Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K, Andersson U, Bjorkhem I, Bergmann Kv, Fassbender K (2004) High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69, 431-438